DermConsult
There’s a lot dermatology specialists need to consider when ensuring patients have healthy skin. And at a time when clinical research is increasingly defining skin conditions—and the practice of dermatology itself—as “more than skin deep,” turn to DermConsult.
In this special series, dermatology specialists share their expert advice on the diagnosis and treatment of a variety of skin conditions. They also explore the latest clinical research and their very own case studies, so you can rest assured you’ll have access to everything you need to know about the body’s largest organ.
91-105 of 184
Rethinking the Routine: Moving from Topicals to Systemics in Psoriasis
DermConsultRethinking the Routine: Moving from Topicals to Systemics in Psoriasis
Christopher Bunick, MD, PhD, FAAD
Targeting Psoriasis at the Source: New Evidence for Interferon Receptor Therapies
DermConsultTargeting Psoriasis at the Source: New Evidence for Interferon Receptor Therapies
Hitting the Target in Atopic Dermatitis: Interdisciplinary Team Training for Leveraging IL-13 Inhibitors to Address the Burden of Disease
CME/CEHitting the Target in Atopic Dermatitis: Interdisciplinary Team Training for Leveraging IL-13 Inhibitors to Address the Burden of Disease
Anne Marie Singh, MD
Recognizing PSO-HS as a Distinct Subset with Shared Genetic Risk
DermConsultRecognizing PSO-HS as a Distinct Subset with Shared Genetic Risk
Unmasking Psoriasis in Skin of Color: Clinical Clues and Care Strategies
DermConsultUnmasking Psoriasis in Skin of Color: Clinical Clues and Care Strategies
Amy McMichael, MD
TYK2 Inhibition with Zasocitinib Delivers Early Benefit Across PsA Domains
DermConsultTYK2 Inhibition with Zasocitinib Delivers Early Benefit Across PsA Domains
- advertisement
How Systemic Psoriasis Therapies Influence the Risk of New or Recurrent MACEs
FCDC Action CenterHow Systemic Psoriasis Therapies Influence the Risk of New or Recurrent MACEs
Combination Therapy for Plaque Psoriasis: A Reappraisal of Cyclosporine and Acitretin
FCDC Action CenterCombination Therapy for Plaque Psoriasis: A Reappraisal of Cyclosporine and Acitretin
Improving Psoriatic Disease Care Through Dermatology–Rheumatology Clinics
FCDC Action CenterImproving Psoriatic Disease Care Through Dermatology–Rheumatology Clinics
Eric Ruderman, MD
Rewriting the Rules of Psoriasis Severity: A Global Shift Toward Impact-Driven Care
FCDC Action CenterRewriting the Rules of Psoriasis Severity: A Global Shift Toward Impact-Driven Care
Understanding Sebopsoriasis: Navigating the Clinical Overlap of Dermatoses
DermConsultUnderstanding Sebopsoriasis: Navigating the Clinical Overlap of Dermatoses
Raj Chovatiya, MD, PhD, MSCI, FAAD
Advancing Care for Coexisting Psoriasis and Seborrheic Dermatitis
DermConsultAdvancing Care for Coexisting Psoriasis and Seborrheic Dermatitis
Raj Chovatiya, MD, PhD, MSCI, FAAD
- advertisement
Guselkumab in Skin of Color: Results from a Randomized Phase 3b Psoriasis Trial
DermConsultGuselkumab in Skin of Color: Results from a Randomized Phase 3b Psoriasis Trial
Targeting Variability: A New Look at Systemic Therapies in Pediatric Severe Atopic Dermatitis
DermConsultTargeting Variability: A New Look at Systemic Therapies in Pediatric Severe Atopic Dermatitis
Pictorial Eczema Education Shows Promise for Improving Patients’ Quality of Life
DermConsultPictorial Eczema Education Shows Promise for Improving Patients’ Quality of Life